Instil Bio(TIL)2025-03-04 12:14Financial Performance - As of December 31, 2024, Instil Bio had total cash, cash equivalents, restricted cash, and marketable securities of 175.0 million as of December 31, 2023[3]. - Research and development expenses for the fourth quarter of 2024 were 2.0 million in the fourth quarter of 2023[6]. - General and administrative expenses for the fourth quarter of 2024 were 10.9 million in the fourth quarter of 2023[7]. - The net loss per share for the fourth quarter of 2024 was 1.99 for the same period in 2023, reflecting a 8.6% improvement[9]. - Instil Bio reported a net loss of 12.9 million in the fourth quarter of 2023[19]. - Total operating expenses for the full year 2024 were 159.2 million in 2023[17]. Future Clinical Developments - The company anticipates clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China to be available in the first half of 2025[4]. - Enrollment of first-line NSCLC patients in a trial of AXN-2510/IMM2510 and chemotherapy in China is expected to begin in Q2 2025[4]. - A U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy for first-line NSCLC patients is anticipated to commence before the end of 2025[4]. Cash Resources - Instil Bio expects its cash resources as of December 31, 2024, to fund its current operating plan beyond 2026[5].